期刊文献+

天门冬氨酸氨基转移酶/血小板比值指数在HBV感染相关疾病中的临床应用 被引量:3

下载PDF
导出
摘要 目的探讨天门冬氨酸氨基转移酶/血小板比值指数(APRI)在乙型肝炎病毒(HBV)感染相关疾病的变化规律,为乙型肝炎病情发展提供实验室依据。方法分别检测134例HBV感染患者和63例健康对照者的透明质酸(HA)、天门冬氨酸氨基转移酶(AST)和血小板计数(PLT),并计算APRI值,比较各指标在乙型肝炎中的变化特点。结果 HBV携带者、慢性乙型肝炎患者、肝硬化患者APRI显著高于健康对照者,差异有统计学意义(P<0.01),且APRI随病情的严重程度呈增高的趋势,各组间患者差异也有统计学意义(P<0.01);各组患者的HA平均值均较健康对照者明显升高(P<0.01),而且随HBV感染病情加重而明显升高(P<0.01);APRI与HA具有相关性(P<0.01)。结论 APRI对于评估慢性乙型病毒性肝炎肝硬化有一定临床价值。
出处 《检验医学与临床》 CAS 2014年第11期1568-1569,共2页 Laboratory Medicine and Clinic
  • 相关文献

参考文献7

  • 1慢性乙型肝炎防治指南[J].中华内科杂志,2006,45(2):162-170. 被引量:185
  • 2赵连荣,许德军,陆忠华,赵鸿,窦晓光,郎振为,王贵强.综合预测模型FibroTest对慢性乙型肝炎肝纤维化的诊断价值[J].中国实用内科杂志,2007,27(16):1274-1277. 被引量:14
  • 3Beom KK, Sung AK, Young NP, et al. Noninvasive mod- els to predict liver cirrhosis in patients with chronic hepa- titis B[J]. Liver International, 2007,27 (7) : 969-976.
  • 4Zeldis JB, Farraye FA, Steinherg HN. Invitro hepatitis B virus suppression of erythropoiesis is dependent on the multiplicity of infection and is reversible with anti-HBs antibodies[J]. Hepatology, 1988,8 (4) : 755-759.
  • 5Okumoto K, Saito T, Onodera M, et al. Serum levels of stem cell factor and thrombopoietin are markedly decrease in fulminant hepatic failure patients with a poor prognosis [J]. J Gastroenterol Hepatol,2007,22(8) : 1265-1270.
  • 6Sanjoa A, Satoi J, Ohnishi A, et al. Role of elevated plate- let-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases[J]. J Gastroen- terol Hepatol,2003,18(6) : 638-644.
  • 7王虹,姚光弼.肝纤维化和肝硬化的非侵入性诊断方法[J].胃肠病学和肝病学杂志,2007,16(1):100-105. 被引量:6

二级参考文献39

  • 1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
  • 2Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients [J]. J Hepatol,2004. 41(6) : 935-942.
  • 3Kelleher TB, Mehta SH, Bhaskar R, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers:the SHASTA index[J]. J Hepatol, 2005, 43(1):78-84.
  • 4Johansen JS, Christoffersen P, Moller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis [J]. J Hepatol, 2000, 32(6):911-920.
  • 5Takahara T, Furui K, Yata Y, et al. Dual expression of matrix metalloproteinase-2 and membrane-type l-matrlx metalloproteinase in fibrotic human livers[J]. Hepatology, 1997, 26(6) :1521-1529.
  • 6Benyon RC, Iredale JP, Goddard S, et al. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver[J]. Gastroenterology, 1996, 110(3) :821-831.
  • 7Shiraishi, T, Morimoto, S, Koh, E, et al. Increased release of platelet-derived growth factor from platelets in chronic liver disease [J].Eur J Clin Chem Clin Biochem, 1994, 32(1):5-9.
  • 8汪月娥.血清生化标志综合模型评估肝纤维化的现况.肝脏,.
  • 9Schuppan D, Ruehl M, Somasundaram R, et al. Matrix as a modulator of hepatic fibrogenesis [J]. Semin Liver Dis, 2001, 21 (3):351-372.
  • 10Harbin WP, Robert N J, Ferrucci JT Jr. Diagnosis of cirrhosis based on regional changes in hepatic morphology: a radiological and pathological analysis[J]. Radiology, 1980, 135(2):273-283.

共引文献202

同被引文献11

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部